Kyntra Bio, Inc.

KYNB

$8.49

-0.47%

2026-09-03 16:00:01 EDT-$0.04

Healthcare

Biotechnology

NASDAQ

Active Trading

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments ...

Historical Employee Count of KYNB

Current

Change

-34.62%

Minimum

Maximum

592

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	34	10-K	Mar 16, 2026	View
Dec 31, 2024	52	10-K	Mar 17, 2025	View
Dec 31, 2023	486	10-K	Feb 26, 2024	View
Dec 31, 2022	592	10-K	Feb 27, 2023	View
Dec 31, 2021	566	10-K	Feb 28, 2022	View

Supply Chain of KYNB

Upstream / Downstream / Proxies

Upstream

Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) — subsidiary of WuXi AppTecSHA:603259Fortis Therapeutics, Inc.Unnamed CDMO Partners (ADC manufacturing)University of California, San Francisco (UCSF)WuXi AppTec (parent of Shanghai SynTheAll/STA)SHA:603259Avalon Ventures / Bregua Corp / Lilly Asia Ventures / Vivo Capital

Downstream

Astellas Pharma Inc.TSE:4503AstraZeneca PLCNASDAQ:AZN Pfizer Inc. (partnered with Astellas on XTANDI/enzalutamide)NYSE:PFEAstellas Pharma US, Inc. / Astellas Europe / Astellas JapanTSE:4503

Proxies

Astellas Pharma Inc.TSE:4503WuXi AppTec Co., Ltd.SHA:603259Akebia Therapeutics, Inc.NASDAQ:AKBAKyowa Kirin Co., Ltd.TSE:4151

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer